Current progress in the targeted therapy of breast cancer: Structure–activity correlation and docking studies (2015–2021)

Despite cancer research and therapy, breast cancer remains a complicated health crisis in women and represents a top biomedical research priority. Nowadays, breast cancer is an extremely heterogeneous disease and is known as the leading cause of death among women worldwide. The incidence and mortality rates of breast cancer have been increasing gradually for the past decades. Nowadays, common treatments for breast cancer are chemotherapy, endocrine therapy, immunotherapy, radiotherapy, and surgery. The most common targets in breast cancer treatment are human epidermal growth factor receptor 2 (HER2) and estrogen receptors. The literature suggests that several targets/pathways are also involved in the development of breast cancer, that is, poly(ADP‐ribose) polymerase (PARP), bromodomain‐containing protein 4 (BRD4), cyclin‐dependent kinase 4/6 (CDK4/6), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), polo‐like kinase 1 (PLK1), phosphoinositide 3‐kinases/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR), histone deacetylase (HDAC), nuclear factor kappa B (NF‐κB), PD‐L1, and aromatase inhibitors. Meanwhile, the study of breast cancer is a hot topic in the current scenario of basic/clinical research. This review article provides information on different targets associated with breast cancer and summarizes the progress of current research on synthesized inhibitors as anti‐breast cancer agents from 2015 to 2021. The review aims to provide structure–activity relationship and docking studies for designing novel compounds for breast cancer therapy. This reviews article provides information on different targets associated with breast cancer and summarizes the progress of current research on synthesized inhibitors as anti‐breast cancer agents, from 2015 to 2021. The aim is to give an overview of structure–activity relationship and docking studies for designing novel compounds for breast cancer therapy.